Table 2. Haplotype frequenciesa by mutation and disease status and HR estimates for breast cancer.

	Unaffected (%)	Affected (%)	HR	95% CI	P-value
BRCA1 mutation carriers
p53 haplotype
No Ins-Arg72/No Ins Arg72b	49.60	50.50	1.00
No Ins-72Pro
Onec	23.30	23.30	1.05	0.84–1.32	0.64
Twod	2.80	2	0.80	0.47–1.38	0.42
Ins16bp-72Pro
One	23.80	23.10	1.03	0.83–1.28	0.79
Two	2.20	2.10	1.16	0.54–2.50	0.70
Ins16bp-Arg72
One	4	3.30	1.42	0.96–2.10	0.08
Two	—	—	—	—	—
BRCA2 mutation carriers
p53 haplotype
No Ins-Arg72/No Ins Arg72	47.50	55.90	1.00
No Ins-72Pro
One	26.50	23.60	0.82	0.53–1.26	0.35
Two	0.90	0.90	1.41	0.56–3.55	0.46
Ins16bp-72Pro
One	26.50	19.40	0.81	0.52–1.27	0.36
Two	2.10	2.20	0.72	0.14–3.86	0.70
Ins16bp-Arg72
One	2	2.70	1.11	0.42–2.97	0.83
Two	—	—	—

Abbreviations: CI=confidence interval; HR=hazard ratio.

HRs corresponding to the haplotype associated with increased cancer risk in the original study are in bold.

^aHaplotypes were established or inferred only in those cases who had data for both polymorphisms.

^bThose individuals who were homozygous for the haplotype containing the common allele for both polymorphisms were considered as the reference group.

^cIndividuals harbouring at least one given haplotype (heterozygous or homozygous)

^dIndividuals homozygous for a given haplotype.